CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 5.68: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.53%Above 5Y avg (1.46%)
Annual Rate
CNY 0.28Paid annual
Payout Ratio
74.2%Moderate
Payback Period
39.6 yr
Last Ex-Dividend
May 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.78BCNY711.12M · vs all stocks (USD)
Trailing P/E
30.11xvs Medical Devices peers
Revenue (TTM)
1.08BCNY161.03M · vs all stocks (USD)
Profit Margin
15.06%vs Medical Devices peers
Beta
0.3740xvs all stocks
52-Week Change
-22.88%vs all stocks
Market Capitalization
4.78BCNY711.12M · vs all stocks (USD)
Enterprise Value
3.58BCNY532.19M · vs all stocks (USD)
Trailing P/E
30.11xvs Medical Devices peers
Forward P/E
9.61xvs Medical Devices peers
Price to Sales (TTM)
4.53xvs Medical Devices peers
Price to Book (MRQ)
2.28xvs Medical Devices peers
Enterprise to Revenue
3.31xvs Medical Devices peers
Enterprise to EBITDA
18.74xvs Medical Devices peers
Gross Margin
61.03%vs Medical Devices peers
Profit Margin
15.06%vs Medical Devices peers
Operating Margin
19.70%vs Medical Devices peers
Return on Assets (TTM)
3.55%vs Medical Devices peers
Return on Equity (TTM)
7.45%vs Medical Devices peers
Revenue (TTM)
1.08BCNY161.03M · vs all stocks (USD)
Revenue per Share (TTM)
2.54CNYUpdated Aug 21, 2026Quarterly Revenue Growth
20.90%vs Medical Devices peers
Gross Profit (TTM)
665.46MCNY98.96M · vs all stocks (USD)
EBITDA (TTM)
211.51MCNY31.45M · vs all stocks (USD)
Net Income (TTM)
163.02MCNY24.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-39.50%vs Medical Devices peers
Operating Cash Flow (TTM)
306.03MCNY45.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
89.45MCNY13.30M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2820CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.53%vs all stocks
5-Year Average Dividend Yield
1.46%vs all stocks
Payout Ratio
74.21%vs Medical Devices peers
Minority Interest (Equity)
-7.05MCNYFY2025 · Dec 31, 2025Revenue
1.04BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
381.85MCNYFY2025 · Dec 31, 2025Gross Profit
655.98MCNYFY2025 · Dec 31, 2025Operating Income
187.87MCNY27.94M · vs all stocks (USD)
Pre-tax Income
180.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.52MCNYFY2025 · Dec 31, 2025Net Income
178.80MCNYFY2025 · Dec 31, 2025EBIT
181.66MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
249.38MCNYFY2025 · Dec 31, 2025Research & Development
228.59MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
86.47MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.15MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
39.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.34MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
428.42MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
428.42MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
178.80MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
182.13MCNYFY2025 · Dec 31, 2025Free Cash Flow
98.90MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.21BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
178.80MCNYFY2025 · Dec 31, 2025Other Non-cash Items
10.79MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
18.08MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.55MCNYFY2025 · Dec 31, 2025Capital Expenditures
-83.22MCNYFY2025 · Dec 31, 2025Purchase of Investments
-92.95MCNYFY2025 · Dec 31, 2025Sale of Investments
97.60MCNYFY2025 · Dec 31, 2025Other Investing Activity
-134.39MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-212.96MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
545.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-748.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-120.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
4.65MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-319.19MCNYFY2025 · Dec 31, 2025Shares Outstanding
428.49MSharesUpdated Aug 21, 2026Float Shares
203.65MSharesUpdated Aug 21, 2026% Held by Insiders
52.85%vs all stocks
% Held by Institutions
7.42%vs all stocks
Total Cash (MRQ)
1.26BCNY188.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.95CNYUpdated Aug 21, 2026Total Debt (MRQ)
149.84MCNY22.28M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0699xvs Medical Devices peers
Current Ratio (MRQ)
4.34xvs Medical Devices peers
Book Value per Share (MRQ)
5.02CNYUpdated Aug 21, 2026Total Assets
2.81BCNY417.80M · vs all stocks (USD)
Total Current Assets
1.96BCNYFY2025 · Dec 31, 2025Total Liabilities
700.79MCNYFY2025 · Dec 31, 2025Total Non-current Assets
852.08MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
4.28MCNYFY2025 · Dec 31, 2025Total Current Liabilities
696.51MCNYFY2025 · Dec 31, 2025Cash
1.55BCNYFY2025 · Dec 31, 2025Cash Equivalents
23.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.57BCNYFY2025 · Dec 31, 2025Accounts Receivable
173.64MCNYFY2025 · Dec 31, 2025Inventory
183.04MCNYFY2025 · Dec 31, 2025Accounts Payable
133.47MCNYFY2025 · Dec 31, 2025Short-term Debt
397.19MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.72MCNYFY2025 · Dec 31, 2025Long-term Debt
841.79KCNYFY2025 · Dec 31, 2025Common Stock (Book)
428.49MCNYFY2025 · Dec 31, 2025Retained Earnings
929.52MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.11BCNY313.59M · vs all stocks (USD)
52-Week Low
9.36CNYUpdated Aug 21, 202652-Week High
14.88CNYUpdated Aug 21, 202652-Week Change
-22.88%vs all stocks
Beta
0.3740xvs all stocks
50-Day MA
10.75CNYUpdated Aug 21, 2026200-Day MA
12.56CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.49MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.60MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3800CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.68: safe zoneNotable
Altman Z-Score: 5.68
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shattuck Labs Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Yunnan Botanee Bio-Technology Group Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Ovctek China Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Shandong Publishing & Media Co., Ltd.
3 interpretationsMinimal Tax and Interest DragPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity